文章引用说明 更多>> (返回到该文章)

Bogdanic-Werner, K., Fernandez-Sanz, G., Alejandre, A.N., et al. (2013) Rituximab therapy for refractory idiopathic scleritis. Ocular Immunology & Inflammation, 21, 329-332.
http://dx.doi.org /10.3109/09273948.2013.788724

被以下文章引用:

  • 标题: 中西医药物治疗巩膜炎的研究进展Review on Treatments of Scleritis with Chinese Medicine and Western Medicine

    作者: 李超然, 张殷建

    关键字: 巩膜炎, 火疳, 中西医, 治疗Scleritis, Episcleritis, Chinese and Western Medicine, Treatment

    期刊名称: 《Traditional Chinese Medicine》, Vol.4 No.3, 2015-08-20

    摘要: 巩膜炎(scleritis),中医称之为“火疳”,为巩膜组织的炎性反应疾病。因巩膜组织由胶原纤维和少量弹性纤维交错致密排列而成,细胞成分和血管较少,导致该疾病并不常见。然而,由于巩膜代谢缓慢,一旦患病,病程往往迁延难愈。在药物治疗上主要有非甾体抗炎药、甾体抗炎药、皮质类固醇药、免疫抑制剂、生物制剂、中药提取物及中药汤剂。本文归纳了上述药物治疗巩膜炎的给药方式及各自临床疗效,分析其中利弊,为临床医疗工作人员提供医疗证据。 Scleritis, also called “episcleritis” in Traditional Chinese Medicine, is an inflammation of sclera tissues. As sclera tissues are compactly composed of collagen fibers and a few of elastic fibers with few cellular constituents and vessels, this disease is uncommon. However, once happened, it has a lingering course due to the slow metabolism of sclera. Drugs mainly include non-steroidal anti-in- flammatory drugs, steroidal anti-inflammatory drugs, corticosteroids, immunosuppressive agent, biological agent, herbal extracts and herbal decoction of Traditional Chinese Medicine. This paper reviewed the administration methods and their clinical effects in treating scleritis with drugs mentioned above, analyzed their advantages and disadvantages, and provided medical evidences for clinical medical staff.

在线客服:
对外合作:
联系方式:400-6379-560
投诉建议:feedback@hanspub.org
客服号

人工客服,优惠资讯,稿件咨询
公众号

科技前沿与学术知识分享